Skip to the page

Data / Drug companies / Slate Run Pharmaceuticals, LLC

Slate Run Pharmaceuticals, LLC: 121 products in the FDA NDC directory, labeler code 70436

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Slate Run Pharmaceuticals, LLC (labeler code 70436) lists 121 products in the FDA National Drug Code Directory, covering 44 finished drugs by generic name. By type: 121 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on October 31, 2026.

The request: Watch Slate Run Pharmaceuticals, LLC (FDA labeler code 70436): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
70436
Products in commercial distribution
121
Packages
194
Finished drugs by generic name
44
Prescription products
121
Over the counter products
0
Flagged as original packager
113 of 113 products that carry the flag
Started marketing in the last 12 months
1
Earliest marketing start
August 2, 2017
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)121100%

Products by type

TypeProductsShare
Prescription drugs121100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection2419.8%
Tablet, extended release2218.2%
Injection, powder, lyophilized, for solution1411.6%
Injection, solution129.9%
Capsule, extended release108.3%
Tablet, film coated86.6%
Powder, for suspension65%
Tablet, film coated, extended release43.3%
Tablet43.3%
Capsule43.3%
Injection, powder, for solution43.3%
Tablet, delayed release21.7%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Mometasone Furoate Monohydrate70436-154Spray, meteredGeneric drugs (ANDA)October 31, 2026
Olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide70436-018Tablet, film coatedGeneric drugs (ANDA)May 15, 2025
Olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide70436-017Tablet, film coatedGeneric drugs (ANDA)May 15, 2025
Olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide70436-016Tablet, film coatedGeneric drugs (ANDA)May 15, 2025
Olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide70436-015Tablet, film coatedGeneric drugs (ANDA)May 15, 2025
Olmesartan medoxomil and amlodipine besylate and hydrochlorothiazide70436-014Tablet, film coatedGeneric drugs (ANDA)May 15, 2025
Gadobutrol70436-218InjectionGeneric drugs (ANDA)April 16, 2025
Gadobutrol70436-217InjectionGeneric drugs (ANDA)April 16, 2025
Gadobutrol70436-217InjectionGeneric drugs (ANDA)April 16, 2025
Gadobutrol70436-216InjectionGeneric drugs (ANDA)April 16, 2025
Gadobutrol70436-216InjectionGeneric drugs (ANDA)April 16, 2025
Gadobutrol70436-213InjectionGeneric drugs (ANDA)April 16, 2025
Cyclophosphamide70436-107Injection, powder, for solutionGeneric drugs (ANDA)March 26, 2025
Cyclophosphamide70436-106Injection, powder, for solutionGeneric drugs (ANDA)March 26, 2025
Cyclophosphamide70436-105Injection, powder, for solutionGeneric drugs (ANDA)March 26, 2025
Gadoteridol70436-121InjectionGeneric drugs (ANDA)February 20, 2025
Leucovorin Calcium70436-119Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)December 27, 2024
Amiodarone Hydrochloride70436-232Injection, solutionGeneric drugs (ANDA)October 31, 2024
Doxycycline hyclate70436-201Powder, for solutionGeneric drugs (ANDA)July 22, 2024
Doxycycline hyclate70436-032Powder, for solutionGeneric drugs (ANDA)July 22, 2024
Methocarbamol70436-149InjectionGeneric drugs (ANDA)July 1, 2024
Gadoterate meglumine70436-123InjectionGeneric drugs (ANDA)June 28, 2024
Gadoterate meglumine70436-123InjectionGeneric drugs (ANDA)June 28, 2024
Iopamidol70436-219Injection, solutionGeneric drugs (ANDA)April 15, 2024
Iopamidol70436-211Injection, solutionGeneric drugs (ANDA)April 15, 2024

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.